Lumatix Biotech GmbH is developing a novel platform for light-controlled affinity chromatography. The so-called Solaris technology revolutionizes antibody purification by enabling gentle, fast and efficient elution without extreme pH values. This increases efficiency, protects sensitive molecules and reduces process costs.
The start-up emerged from Prof. Dirk Weuster-Botz´s Chair of Biochemical Engineering. In addition to conventional start-up funding such as EXIST, the TUM research ecosystem in Garching was crucial to the company's success. In light-switchable affinity chromatography, biotechnology goes hand in hand with organic chemistry, prototyping, electronics and optics. This was helpful for the integration into the interdisciplinary Chair of Bioprocess Engineering, coupled with short distances to chemistry departments, laboratories and supporting facilities such as the makerspace, in order to further develop various interlocking technologies in short cycle times.
The principle is broadly applicable and the company intends to further apply its technology with new partnerships. Congratulations on winning the award!
More information:
www.innovationspreis-der-bioregionen.de